Evaluation of aminoglycoside and carbapenem resistance in a collection of drug-resistant pseudomonas aeruginosa clinical isolates

Microbial Drug Resistance

Volumn 24, Issue 7, 2018, Pages 1020-1030

  Holbrook, Selina Y L ^a   Garneau Tsodikova, Sylvie ^a  

^a University of Kentucky   (United States)

Author keywords

aminoglycoside modifying enzymes (AMEs); drug combination; ESKAPE pathogens; resistance patterns

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE DERIVATIVE; APRAMYCIN; CARBAPENEM DERIVATIVE; GENTAMICIN; IMIPENEM; MEROPENEM; NETILMICIN; SISOMICIN; TOBRAMYCIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENETICS; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATION; IN VITRO STUDY; KENTUCKY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; UNIVERSITY HOSPITAL; DRUG EFFECT; GENETICS; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; CARBAPENEMS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 85053127340     PISSN: 10766294     EISSN: 19318448     Source Type: Journal    
DOI: 10.1089/mdr.2017.0101     Document Type: Article

References (57)

1. Boucher, H.W., G.H. Talbot, J.S. Bradley, J.E. Edwards, D. Gilbert, L.B. Rice, M. Scheld, B. Spellberg, J.Bartlett. 2009. Bad bugs, no drugs: NoESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48:1-12.
2. Narten, M., N. Rosin, M. Schobert, P. Tielen. 2012. Susceptibility of Pseudomonas aeruginosa urinary tract isolates and influence of urinary tract conditions on antibiotic tolerance. Curr. Microbiol. 64:7-16.
3. Obritsch, M.D., D.N. Fish, R. MacLaren, R. Jung. 2005. Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: Epidemiology and treatment options. Pharmacotherapy. 25:1353-1364.
4. Pendleton, J.N., S.P. Gorman, B.F. Gilmore. 2013. Clinical relevance of the ESKAPE pathogens. Expert Rev. Anti Infect. Ther. 11:297-308.
5. Pobiega, M., J. Maciag, A. Chmielarczyk, D. Romaniszyn, M. Pomorska-Wesolowska, G. Ziolkowski, P.B. Heczko, M. Bulanda, J. Wojkowska-Mach. 2015. Molecular characterization of carbapenem-resistant Pseudomonas aeruginosa strains isolated from patients with urinary tract infections in Southern Poland. Diagn. Microbiol. Infect. Dis. 83:295-297.
6. Qiu, X., B.R. Kulasekara, S. Lory. 2009. Role of horizontal gene transfer in the evolution of Pseudomonas aeruginosa virulence. Genome Dyn. 6:126-139.
7. Rice, L.B. 2010. Progress and challenges in implementing the research on ESKAPE pathogens. Infect. Control Hosp. Epidemiol. 31 Suppl 1:S7-S10.
8. Hirsch, E.B., V.H. Tam. 2010. Impact of multidrugresistant Pseudomonas aeruginosa infection on patient outcomes. Expert Rev. Pharmacoecon. Outcomes Res. 10: 441-451.
9. National Nosocomial Infection Surveillance (NNIS) system report: Data summary from January 1992 through June 2003. Available at www.cdc.gov/ncidod/dhqp/pdf (accessed July 13, 2017).
10. Fujitani, S., K.S. Moffett, V.L. Yu. 2017. Pseudomonas aeruginosa, antimicrobe: Infectious disease & antimicrobial agents. Available at www.antimicrobe.org/new/b112.asp (accessed July 13, 2017).
11. Calhoun, J.H., C.K. Murray, M.M. Manring. 2008. Multidrug-resistant organisms in military wounds from Iraq and Afghanistan. Clin. Orthop. Relat. Res. 466:1356-1362.
12. Fosso, M.Y., Y. Li, S. Garneau-Tsodikova. 2014. New trends in aminoglycosides use. MedChemComm 5:1075-1091.
13. Matt, T., C.L. Ng, K. Lang, S.H. Sha, R. Akbergenov, D. Shcherbakov, M. Meyer, S. Duscha, J. Xie, S.R. Dubbaka, D. Perez-Fernandez, A. Vasella, V. Ramakrishnan, J. Schacht, E.C. Bottger. 2012. Dissociation of antibacterial activity and aminoglycoside ototoxicity in the 4-monosubstituted 2-deoxystreptamine apramycin. Proc. Natl. Acad. Sci. U. S. A. 109:10984-10989.
14. Kang, A.D., K.P. Smith, G.M. Eliopoulos, A.H. Berg, C. McCoy, J.E. Kirby. 2017. In vitro apramycin activity against multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Diagn. Microbiol. Infect. Dis. 88:188-191.
15. Karlowsky, J.A., D.J. Hoban, M.A. Hackel, S.H. Lob, D.F. Sahm. 2017. Antimicrobial susceptibility of Gramnegative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Asia-Pacific countries: SMART 2013-2015. J. Med. Microbiol. 66:61-69.
16. Biedenbach, D.J., P.T. Giao, P. Hung Van, N. Su Minh Tuyet, T. Thi Thanh Nga, D.M. Phuong, N. Vu Trung, R.E. Badal. 2016. Antimicrobial-resistant Pseudomonas aeruginosa and Acinetobacter baumannii from patients with hospital-acquired or ventilator-associated pneumonia in Vietnam. Clin. Ther. 38:2098-2105.
17. Chen, W., T. Biswas, V.R. Porter, O.V. Tsodikov, S. Garneau-Tsodikova. 2011. Unusual regioversatility of acetyltransferase Eis, a cause of drug resistance in XDRTB. Proc. Natl. Acad. Sci. U. S. A. 108:9804-9808.
18. Chen, W., K.D. Green, O.V. Tsodikov, S. Garneau-Tsodikova. 2012. Aminoglycoside multiacetylating activity of the enhanced intracellular survival protein from Mycobacterium smegmatis and its inhibition. Biochemistry 51: 4959-4967.
19. Green, K.D., W. Chen, S. Garneau-Tsodikova. 2012. Identification and characterization of inhibitors of the aminoglycoside resistance acetyltransferase Eis from Mycobacterium tuberculosis. ChemMedChem 7:73-77.
20. Houghton, J.L., K.D. Green, R.E. Pricer, A.S. Mayhoub, S. Garneau-Tsodikova. 2013. Unexpected N-acetylation of capreomycin by mycobacterial Eis enzymes. J. Antimicrob. Chemother. 68:800-805.
21. Houghton, J.L., T. Biswas, W. Chen, O.V. Tsodikov, S. Garneau-Tsodikova. 2013. Chemical and structural insights into the regioversatility of the aminoglycoside acetyltransferase Eis. ChemBioChem 14:2127-2135.
22. Tsodikov, O.V., K.D. Green, S. Garneau-Tsodikova. 2014. A random sequential mechanism of aminoglycoside acetylation by Mycobacterium tuberculosis Eis protein. PLoS One 9:e92370.
23. Ramirez, M.S., M.E. Tolmasky. 2010. Aminoglycoside modifying enzymes. Drug Resist. Updat. 13:151-171.
24. Houghton, J.L., K.D. Green, W. Chen, S. Garneau-Tsodikova. 2010. The future of aminoglycosides: The end or renaissance ChemBioChem 11:880-902.
25. Li, Y., K.D. Green, B.R. Johnson, S. Garneau-Tsodikova. 2015. Inhibition of aminoglycoside acetyltransferase resistance enzymes by metal salts. Antimicrob. Agents Chemother. 59:4148-4156.
26. Shaul, P., K.D. Green, R. Rutenberg, M. Kramer, Y. Berkov-Zrihen, E. Breiner-Goldstein, S. Garneau-Tsodikova, M. Fridman. 2011. Assessment of 6¢-A nd 6¢¢¢-N-acylation of aminoglycosides as a strategy to overcome bacterial resistance. Org. Biomol. Chem. 9:4057-4063.
27. Green, K.D., W. Chen, S. Garneau-Tsodikova. 2011. Effects of altering aminoglycoside structures on bacterial resistance enzyme activities. Antimicrob. Agents Chemother. 55:3207-3213.
28. Thamban Chandrika, N., K.D. Green, J.L. Houghton, S. Garneau-Tsodikova. 2015. Synthesis and biological activity of mono-A nd di-N-acylated aminoglycosides. ACS Med. Chem. Lett. 6:1134-1139.
29. Fong, D.H., B. Xiong, J. Hwang, A.M. Berghuis. 2011. Crystal structures of two aminoglycoside kinases bound with a eukaryotic protein kinase inhibitor. PLoS One 6: E19589.
30. Lopez, C., B.A. Arivett, L.A. Actis, M.E. Tolmasky. 2015. Inhibition of AAC(6¢)-Ib-mediated resistance to amikacin in Acinetobacter baumannii by an antisense peptide-conjugated 2¢, 4¢-bridged nucleic acid-NC-DNA hybrid oligomer. Antimicrob. Agents Chemother. 59:5798-5803.
31. Shakya, T., P.J. Stogios, N. Waglechner, E. Evdokimova, L. Ejim, J.E. Blanchard, A.G. McArthur, A. Savchenko, G.D. Wright. 2011. A small molecule discrimination map of the antibiotic resistance kinome. Chem. Biol. 18: 1591-1601.
32. Welch, K.T., K.G. Virga, N.A. Whittemore, C. Ozen, E. Wright, C.L. Brown, R.E. Lee, E.H. Serpersu. 2005. Discovery of non-carbohydrate inhibitors of aminoglycosidemodifying enzymes. Bioorg. Med. Chem. 13:6252-6263.
33. Zhang, W., Y. Chen, Q. Liang, H. Li, H. Jin, L. Zhang, X. Meng, Z. Li. 2013. Design, synthesis, antibacterial activities of conformationally constrained kanamycin A derivatives. J. Org. Chem. 78:400-409.
34. Fair, R.J., M.E. Hensler, W. Thienphrapa, Q.N. Dam, V. Nizet, Y. Tor. 2012. Selectively guanidinylated aminoglycosides as antibiotics. ChemMedChem 7:1237-1244.
35. Tsai, A., S. Uemura, M. Johansson, E.V. Puglisi, R.A. Marshall, C.E. Aitken, J. Korlach, M. Ehrenberg, J.D. Puglisi. 2013. The impact of aminoglycosides on the dynamics of translation elongation. Cell Rep. 3:497-508.
36. Llano-Sotelo, B., R.P. Hickerson, L. Lancaster, H.F. Noller, A.S. Mankin. 2009. Fluorescently labeled ribosomes as a tool for analyzing antibiotic binding. RNA 15: 1597-1604.
37. Chang, C.W., M. Fosso, Y. Kawasaki, S. Shrestha, M.F. Bensaci, J. Wang, C.K. Evans, J.Y. Takemoto. 2010. Antibacterial to antifungal conversion of neamine aminoglycosides through alkyl modification. Strategy for reviving old drugs into agrofungicides. J. Antibiot. 63:667-672.
38. Maianti, J.P., H. Kanazawa, P. Dozzo, R.D. Matias, L.A. Feeney, E.S. Armstrong, D.J. Hildebrandt, T.R. Kane, M.J. Gliedt, A.A. Goldblum, M.S. Linsell, J.B. Aggen, J. Kondo, S. Hanessian. 2014. Toxicity modulation, resistance enzyme evasion, A-site X-ray structure of broad-spectrum antibacterial neomycin analogs. ACS Chem. Biol. 9:2067-2073.
39. Duscha, S., H. Boukari, D. Shcherbakov, S. Salian, S. Silva, A. Kendall, T. Kato, R. Akbergenov, D. Perez-Fernandez, B. Bernet, S. Vaddi, P. Thommes, J. Schacht, D. Crich, A. Vasella, E.C. Bottger. 2014. Identification and evaluation of improved 4¢-O-(alkyl) 4, 5-disubstituted 2-deoxystreptamines as next-generation aminoglycoside antibiotics. mBio. 5:e01827-01814.
40. Nakamura, A., M. Hosoda, T. Kato, Y. Yamada, M. Itoh, K. Kanazawa, H. Nouda. 2000. Combined effects of meropenem and aminoglycosides on Pseudomonas aeruginosa in vitro. J. Antimicrob. Chemother. 46:901-904.
41. Ferrara, A., G. Grassi, F.A. Grassi, P.D. Piccioni, G. Gialdroni Grassi. 1989. Bactericidal activity of meropenem and interactions with other antibiotics. J. Antimicrob. Chemother. 24 Suppl A:239-250.
42. Kropec, A., S. Lemmen, M. Wursthorn, F.D. Daschner. 1994. Combination effect of meropenem with aminoglycosides and teicoplanin on Pseudomonas and enterococci. Infection 22:306-308.
43. Oie, S., A. Sawa, A. Kamiya, H. Mizuno. 1999. In-vitro effects of a combination of antipseudomonal antibiotics against multi-drug resistant Pseudomonas aeruginosa. J. Antimicrob. Chemother. 44:689-691.
44. Clinical and Laboratory Standards Institute. 2012. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Approved Standard. 9th ed. CLSI document M07-A9. Wayne, PA.
45. Clinical and Laboratory Standards Institute. 2014. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fourth Informational Supplement. CLSI document M100-S24. Wayne PA
46. Wayne, PA. 46. Barry, A.L., G.H. Miller, R.S. Hare, R.N. Jones, C. Thornsberry. 1984. Modification of interpretive breakpoints for netilmicin disk susceptibility tests with Pseudomonas aeruginosa. J. Clin. Microbiol. 19:311-314.
47. Barry, A.L., C. Thornsberry, R.N. Jones, E.H. Gerlach. 1981. Gentamicin, tobramycin, sisomicin disc susceptibility tests. Revised zone standards for interpretation. Am. J. Clin. Pathol. 75:524-531.
48. Almaghrabi, R., C.J. Clancy, Y. Doi, B. Hao, L. Chen, R.K. Shields, E.G. Press, N.M. Iovine, B.M. Townsend, M.M. Wagener, B. Kreiswirth, M.H. Nguyen. 2014. Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents. Antimicrob. Agents Chemother. 58:4443-4451.
49. Watkins, D., S. Kumar, K.D. Green, D.P. Arya, S. Garneau-Tsodikova. 2015. Influence of linker length and composition on enzymatic activity and ribosomal binding of neomycin dimers. Antimicrob. Agents Chemother. 59: 3899-3905.
50. Meletiadis, J., J.W. Mouton, J.F. Meis, P.E. Verweij. 2003. In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob. Agents Chemother. 47:106-117.
51. Hawkey, P.M., A.M. Jones. 2009. The changing epidemiology of resistance. J. Antimicrob. Chemother. 64 Suppl 1:i3-i10.
52. Grall, N., V. Lazarevic, N. Gaia, C. Couffignal, C. Laouenan, E. Ilic-Habensus, I. Wieder, P. Plesiat, C. Angebault, M.E. Bougnoux, L. Armand-Lefevre, A. Andremont, X. Duval, J. Schrenzel. 2017. Unexpected persistence of extended-spectrum beta-lactamase-producing Enterobacteriaceae in the faecal microbiota of hospitalised patients treated with imipenem. Int. J. Antimicrob. Agents. 50:81-87.
53. Hansen, K.C.M., Schwensen, S. A. F., D.P. Henriksen, U.S. Justesen, T.V. Sydenham. 2017. Antimicrobial resistance in the Bacteroides fragilis group in faecal samples from patients receiving broad-spectrum antibiotics. Anaerobe 47:79-85.
54. Chuanchuen, R., K. Beinlich, T.T. Hoang, A. Becher, R.R. Karkhoff-Schweizer, H.P. Schweizer. 2001. Crossresistance between triclosan and antibiotics in Pseudomonas aeruginosa is mediated by multidrug efflux pumps: Exposure of a susceptible mutant strain to triclosan selects nfxB mutants overexpressing MexCD-OprJ. Antimicrob. Agents Chemother. 45:428-432.
55. Yadav, R., C.B. Landersdorfer, R.L. Nation, J.D. Boyce, J.B. Bulitta. 2015. Novel approach to optimize synergistic carbapenem-aminoglycoside combinations against carbapenem-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 59:2286-2298.
56. Clock, S.A., S. Tabibi, L. Alba, C.J. Kubin, S. Whittier, L. Saiman. 2013. In vitro activity of doripenem alone and in multi-agent combinations against extensively drugresistant Acinetobacter baumannii and Klebsiella pneumoniae. Diagn. Microbiol. Infect. Dis. 76:343-346.
57. Principe, L., A. Capone, A. Mazzarelli, S. D'Arezzo, E. Bordi, Di Caro, A., N. Petrosillo. 2013. In vitro activity of doripenem in combination with various antimicrobials against multidrug-resistant Acinetobacter baumannii: Possible options for the treatment of complicated infection. Microb. Drug Resist. 19:407-414.